Trial Profile
Safety and efficacy of AVP-923 [dextromethorphan/quinidine] for pseudobulbar affect in multiple sclerosis patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jul 2016
Price :
$35
*
At a glance
- Drugs Dextromethorphan/quinidine (Primary)
- Indications Emotional lability
- Focus Therapeutic Use
- Sponsors Avanir Pharmaceuticals
- 26 Dec 2007 Status changed from in progress to completed.
- 09 Oct 2005 New trial record.